BY OUR PLATFORMS
BY THERAPEUTIC AREA
01 July 2023 - 01 July 2025
01 January 2023 - 30 June 2025
01 December 2022 - 30 November 2025
The project will use patient derived-iPSC and CRISPR-edited human IPSC to develop a novel three-dimensional microfluidic system for drug discovery.
01 October 2022 - 30 September 2027
The EdiGenT consortium will work to develop a new generation of more efficient gene correction tools based on the CRISPR/Cas9 system, and non-viral delivery strategies for gene therapy.
01 March 2022 - 01 March 2023
Eleva Group has assisted ZeClinics in the installation of a Customer Relationship Management (CRM).
01 January 2022 - 30 June 2023
ZeBYTE aims at using artificial intelligence technologies along the whole target discovery process.
01 August 2021 - 01 August 2023
A cutting-edge gene-editing platform to generate complex disease models to test innovative therapeutic approaches.
01 April 2021 - 31 March 2024
The ROBO-FISH consortium will develop and validate injection and imaging robots to automate oncology drug screening in zebrafish to mimic human disease.
01 December 2020 - 30 November 2023
CARDIOMYO combines three complementary approaches: 1) high content phenotypic in vitro cardiac assays 2) a novel in vivo cardiovascular phenotyping using zebrafish and 3) drug discovery chemistry
01 September 2020 - 31 August 2023
Our purpose is to isolate nanobodies that bind cancer stemm cells and have a direct cytotoxic effect on them, or could act as carriers of cytotoxic drugs specifically towards them.
01 January 2020 - 31 December 2023
SCilS is training a new generation of scientists to characterise ciliopathies, an increasingly important and diverse class of inherited diseases.
01 January 2020 - 31 December 2024
REANIMA aims to deliver new therapies for heart regeneration, thereby reverting the conditions that lead to heart failure.
01 October 2019 - 30 September 2023
The EU-funded ZENITH project is preparing a new generation of scientists for interdisciplinary collaboration on pressing neuroscience challenges utilising the zebrafish model system.
01 June 2019 - 31 May 2021
We propose the development of a high-throughput preclinical platform using the zebrafish model to find suitable treatments for heart regeneration after ischemia.
01 December 2018 - 31 May 2021
The concept of the InnoTCM project is to apply an innovative approach to profiling the TCM herb extracts by using Zebrafish as a model organism in High Throughput Screening (HTS) manner.
Please leave your details in the form below.